Compare · DXCM vs GNMK
DXCM vs GNMK
Side-by-side comparison of DexCom Inc. (DXCM) and GenMark Diagnostics, Inc. (GNMK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and GNMK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM carries a market cap of $27.61B.
- DXCM has hit the wire 6 times in the past 4 weeks while GNMK has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 0 for GNMK).
- Company
- DexCom Inc.
- GenMark Diagnostics, Inc.
- Price
- $71.54+1.52%
- -
- Market cap
- $27.61B
- -
- 1M return
- +2.57%
- -
- 1Y return
- -20.08%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2010
- News (4w)
- 6
- 0
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
- Executive Chair Sayer Kevin R sold $2,041,999 worth of shares (26,756 units at $76.32) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 328,970 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
Latest GNMK
- Gene Panel Market size worth $ 8.22 Million, Globally, by 2028 at 21.36% CAGR: Verified Market Research®
- SEC Form SC 13G/A filed by GenMark Diagnostics, Inc. (Amendment)
- SEC Form 15-12B filed by GenMark Diagnostics, Inc.
- SEC Form EFFECT filed by GenMark Diagnostics, Inc.
- SEC Form S-8 POS filed by GenMark Diagnostics, Inc.
- SEC Form S-8 POS filed by GenMark Diagnostics, Inc.
- SEC Form S-8 POS filed by GenMark Diagnostics, Inc.
- SEC Form S-8 POS filed by GenMark Diagnostics, Inc.
- SEC Form S-8 POS filed by GenMark Diagnostics, Inc.
- SEC Form S-8 POS filed by GenMark Diagnostics, Inc.